2016-2030年中国、法国、德国、意大利、日本、西班牙、英国和美国非酒精性脂肪性肝病疾病负担建模
该分析采用马尔可夫模型,基于八国成人肥胖和2型糖尿病患病率数据,预测2016-2030年非酒精性脂肪性肝病(NAFLD)和非酒精性脂肪性肝炎(NASH)的疾病进展。若肥胖和糖尿病水平趋于平稳,NAFLD总病例数将温和增长0-30%,但NASH患病率将增加15-56%,肝病死亡和晚期肝病将增加一倍以上。
要点
- 若肥胖和糖尿病平稳,2016-2030年NAFLD总病例数增长0-30%,中国增幅最高,日本最低。
- 同期NASH患病率将增加15-56%,肝病死亡和晚期肝病将增加一倍以上。
- 若肥胖和糖尿病按当前和历史速率继续增加,NAFLD和NASH患病率预计均将上升。
核心结论
- NAFLD和NASH是庞大且不断增长的公共卫生问题,需要努力了解该流行病并减轻疾病负担。
- 若肥胖和糖尿病按当前和历史速率继续增加,NAFLD和NASH患病率预计均将上升。
- 由于两者均可逆转,提高认识和诊断并促进饮食和运动的公共卫生运动有助于管理未来疾病负担的增长。
研究设计与样本
- 使用马尔可夫模型,基于八个国家成人肥胖和2型糖尿病患病率数据,估计NAFLD和NASH疾病进展。
- 使用已发表的估计值和专家共识构建并验证模型预测。
主要发现
- 若肥胖和糖尿病水平趋于平稳,2016-2030年NAFLD总病例数将温和增长0-30%,中国增幅最高(因城市化),日本最低(因人口萎缩)。
- 同期NASH患病率将增加15-56%,肝病死亡和晚期肝病将增加一倍以上(因人口老龄化和增长)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are increasingly a cause of cirrhosis and hepatocellular carcinoma globally. This burden is expected to increase as epidemics of obesity, diabetes and metabolic syndrome continue to grow. The goal of this analysis was to use a Markov model to forecast NAFLD disease burden using currently available data. METHODS: A model was used to estimate NAFLD and NASH disease progression in eight countries based on data for adult prevalence of obesity and type 2 diabetes mellitus (DM). Published estimates and expert consensus were used to build and validate the model projections. RESULTS: If obesity and DM level off in the future, we project a modest growth in total NAFLD cases (0-30%), between 2016-2030, with the highest growth in China as a result of urbanization and the lowest growth in Japan as a result of a shrinking population. However, at the same time, NASH prevalence will increase 15-56%, while liver mortality and advanced liver disease will more than double as a result of an aging/increasing population. CONCLUSIONS: NAFLD and NASH represent a large and growing public health problem and efforts to understand this epidemic and to mitigate the disease burden are needed. If obesity and DM continue to increase at current and historical rates, both NAFLD and NASH prevalence are expected to increase. Since both are reversible, public health campaigns to increase awareness and diagnosis, and to promote diet and exercise can help manage the growth in future disease burden. LAY SUMMARY: Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis can lead to advanced liver disease. Both conditions are becoming increasingly prevalent as the epidemics of obesity and diabetes continue to increase. A mathematical model was built to understand how the disease burden associated with non-alcoholic fatty liver disease and non-alcoholic steatohepatitis will change over time. Results suggest increasing cases of advanced liver disease and liver-related mortality in the coming years.
引用
- Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol. 2018. PMID: 29886156. doi:10.1016/j.jhep.2018.05.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。